Targeting pediatric cancer stem cells with oncolytic virotherapy
/in International Publications, Newcastle Disease VirusSodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses
/in Hyperthermia, International Publications, Ovarian CancerQuality of life during dendritic cell vaccination against metastatic renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International PublicationsHER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
/in Breast Cancer, Dendritic Cells, International PublicationsNewcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity
/in International Publications, Newcastle Disease Virus, Pancreatic CancerImmunotherapy for metastatic colorectal cancer: present status and new options
/in Colorectal Cancer, Dendritic Cells, International PublicationsClinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsEffector CD8+ T cell IFN-γ production and cytotoxicity are enhanced by mild hyperthermia
/in Hyperthermia, International PublicationsInhibition of checkpoint kinase 1 abrogates G2/M checkpoint activation and promotes apoptosis under heat stress
/in Hyperthermia, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer